Definitions for every acronym and term used across the BioinvestGPT BVCT platform.
This reference defines the acronyms, scientific terms, and platform-specific concepts that appear throughout the BioinvestGPT BVCT user guide and UI. Terms are listed alphabetically. Use your browser's find (Ctrl/Cmd + F) to jump to a term.
| Term | Definition |
|---|---|
| ADMET | Absorption, Distribution, Metabolism, Excretion, Toxicity — key pharmacokinetic properties of a drug |
| BVCT | BioinvestGPT Virtual Clinical Trial — the platform's core prediction engine that estimates clinical outcomes before actual trials |
| CDP | Candidate Drug Profile — the milestone where a drug candidate is formally selected for development |
| CDR | Complementarity-Determining Region — the hypervariable loops in antibodies that bind to antigens |
| DAR | Drug-to-Antibody Ratio — the average number of drug molecules conjugated to each antibody in an ADC |
| DDI | Drug-Drug Interaction — potential interaction between two drugs taken together |
| ECOG | Eastern Cooperative Oncology Group — performance status scale (0-5) measuring patient fitness |
| eGFR | Estimated Glomerular Filtration Rate — kidney function measure (mL/min/1.73m²) |
| Example hypothesis | A pre-loaded, curated target/drug hypothesis (13 total in the Load Example(s) popup) spanning major therapeutic areas and modalities. Picking one seeds the disease, target regulation, and — for Enhancement-ready examples — the drug-design brief in one click. |
| Enhancement-ready | Badge on an Example card indicating the example includes a complete drug-design brief (seed drug, modality, target protein, developability goals, PK targets). Picking such an example pre-populates the ENHANCEMENT BVCT workflow end-to-end. |
| GO/NO-GO | Binary decision: advance (GO) or terminate (NO-GO) a program based on predicted effect size |
| HbA1c | Glycated hemoglobin — 3-month average blood sugar measure for diabetes |
| HELM | Hierarchical Editing Language for Macromolecules — notation standard for complex biologics |
| HR | Hazard Ratio — ratio of event rates between treatment and control groups. HR < 1 favors treatment. |
| ICH | International Council for Harmonisation — sets global pharmaceutical regulatory standards |
| IND | Investigational New Drug — FDA application to begin human clinical trials |
| Lipinski Rule of 5 | Predicts oral bioavailability: MW<500, LogP<5, HBD≤5, HBA≤10 |
| mAb | Monoclonal Antibody — lab-made protein that binds specific targets |
| NCT ID | National Clinical Trial Identifier — unique ID on ClinicalTrials.gov (e.g., NCT04567890) |
| NDA | New Drug Application — FDA submission for marketing approval |
| OR | Odds Ratio — ratio of odds of an event in treatment vs control. OR > 1 favors treatment. |
| PD-L1 | Programmed Death-Ligand 1 — immune checkpoint protein; biomarker for immunotherapy response |
| PK/PD | Pharmacokinetics (what the body does to the drug) / Pharmacodynamics (what the drug does to the body) |
| PrimeKG | Precision Medicine Knowledge Graph — 130K+ biomedical entities, 8M+ relationships |
| Randomize | The shuffle button in the Load Example(s) popup header — picks one example uniformly at random from the currently-filtered list (respects the active therapeutic-area chip). |
| RECIST | Response Evaluation Criteria in Solid Tumors — standardized tumor response measurement |
| SAR | Structure-Activity Relationship — how molecular structure changes affect biological activity |
| SoC | Standard of Care — current best available treatment (the benchmark) |
| TCP | Target Candidate Profile — the milestone where a biological target is formally selected for drug discovery |
| TPP | Target Product Profile — FDA-recommended document defining desired drug characteristics |
| TPSA | Topological Polar Surface Area — molecular property predicting membrane permeability |
BioinvestGPT BVCT Platform User Guide — Glossary. BVCT outputs are model-based decision-support analyses, not investment advice. Prospective track record: data.bioinvestgpt.com.